骨疏康联合阿仑膦酸钠治疗老年糖尿病性骨质疏松疗效分析  

Efficacy of Gushukang granules combined with alendronate sodium in the treatment of diabetic osteoporosis

作　　者：周春 禹翔 费明峰 洪逸莲 吴玉泉 Zhou Chun;Yu Xiang;Fei Mingfeng;Hong Yilian;Wu Yuquan(Department of Geriatrics,the 903 Hospital of the Chinese PLA Joint Support Force,Hangzhou 310013,China)

机构地区：[1]中国人民解放军联勤保障部队第九〇三医院老年医学科,杭州310013

出　　处：《中华老年病研究电子杂志》2022年第3期25-28,共4页Chinese Journal of Geriatrics Research(Electronic Edition)

摘　　要：目的探讨骨疏康联合阿仑膦酸钠治疗老年糖尿病性骨质疏松的临床疗效。方法选取2018年7月至2021年7月中国人民解放军联勤保障部队第九〇三医院收治的糖尿病性骨质疏松患者80例,随机分为两组。其中40例给予阿仑膦酸钠和碳酸钙D3片(对照组),余40例在对照组基础上加用骨疏康治疗(观察组)。连续治疗6个月后比较两组患者的视觉模拟评分(VAS)、功能障碍指数(ODI)评分、骨密度、骨代谢指标、糖尿病相关指标及不良反应发生情况。计量资料的组间比较采用t检验,计数资料的组间比较采用χ^(2)检验。结果观察组患者治疗总有效率明显高于对照组(χ^(2)=8.793,P<0.05),不良反应发生率明显低于对照组(χ^(2)=6.254,P<0.05)。治疗后,观察组患者VAS、ODI评分以及血清钙、骨碱性磷酸酶、总Ⅰ型胶原蛋白氨基端延长肽、Ⅰ型胶原羧基末端肽、氨基端中段骨钙素水平的改善程度均较对照组更明显(t=7.909、13.310、3.535、3.361、2.107、3.211、5.667,P<0.05)。结论骨疏康联合阿仑膦酸钠能够有效改善糖尿病性骨质疏松患者的治疗效果,且安全性良好。Objective To observe the efficacy of Gushukang granules combined with alendronate sodium in the treatment of diabetic osteoporosis(DOP).Methods Eighty patients with DOP admitted to the 903 Hospital of the Chinese PLA Joint Support Force during July 2018 and July 2021 were randomly divided into control group and observation group,with 40 cases in each group.The control group was given alendronate sodium and calcium carbonate D3 tablets,and the observation group was treated with Gushukang in addition.After 6 months of continuous treatment,the visual analogue score(VAS),quality of life Oswestry disability index(ODI)score,the bone mineral density(BMD),the biochemical indexes related to bone metabolism,diabetes control indexes and the occurrence of adverse drug reactions were compared between two groups.Measurement data and count data were compared between groups using t test orχ^(2) test,respectively.Results The total effective rate of the observation group was significantly higher than that of the control group(χ^(2)=8.793,P<0.05).The incidence of adverse reactions in the observation group was significantly lower than that in the control group(χ^(2)=6.254,P<0.05).After treatment,the VAS,ODI scores,serum calcium,bone alkaline phosphatase,total typeⅠcollagen amino-terminal prolongating peptide,typeⅠcollagen carboxyl terminal peptide and amino-terminal osteocalcin in the observation group were significantly improved compared with those in the control group(t=7.909,13.310,3.535,3.361,2.107,3.211,5.667;P<0.05).Conclusion Gushukang combined with alendronate sodium is effective and safe for the patients with DOP.

关 键 词：骨疏康颗粒 阿仑膦酸钠 糖尿病性骨质疏松 疗效 不良反应 老年人 

分 类 号：R587.1[医药卫生—内分泌] R681[医药卫生—内科学]